CARLSBAD, Calif., Feb. 24, 2009 (GLOBE NEWSWIRE) — Alphatec Holdings, Inc. (NasdaqGM:ATEC – News), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine today announced several key activities that will take place during the 2009 Annual Meeting of the Academy of Orthopedic Surgeons being held February 25-28 in Las Vegas, NV at the Venetian/Sands EXPO. Of note, Alphatec Spine will release one new product and begin the full market launch of two new products, along with sponsoring a presentation by industry expert Robin Young to educate attendees on the aging spine marketplace.
Product Line Additions
Alphatec Spine announced the market launch of its Universal Novel(r) Anterior Lumbar Interbody Fusion (ALIF) System as well as the full commercial release of its OsseoFix+ Cement System and its Vacuum Infusion Packaging, or VIP system. The announcements were made in conjunction with the start of the 2009 Annual AAOS Meeting in Las Vegas.
The Universal ALIF is a comprehensive solution for both the Novel PEEK and AlphaGRAFT(r) Allograft implants in one system. The innovative inserter/distracter contained in the system provides for controlled distraction and precise insertion for Alphatec Spine’s PEEK and allograft implants. The implants are available in multiple footprints and lordotic angles to provide solutions for all levels and patient anatomies. In 2008 it is estimated that 80,000 ALIF procedures were performed in the U.S., which created a $350 million market.
Alphatec Spine also announced the full market launch of the OsseoFix+ Cement System. The OsseoFix+ Cement System has a patented mixing and delivery system for treating vertebral compression fractures (VCF). Currently, the two most common procedures used to treat a VCF are kyphoplasty and vertebroplasty. A vertebroplasty procedure involves injecting bone cement directly into the VCF under high pressure, with the goal of stabilizing the fracture. In 2008 it is estimated that the U.S. market for the treatment of VCFs was $540 million.